MDL-101

N/A

Report date: 2025/08/29 17:06:03

Base Information

Drug NameMDL-101
Drug Alias NameMDL-101
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR
Mechanisms of ActionLaminin subunit alpha-1 stimulants
TargetsLaminin subunit alpha-1
Therapy Area/IndicationsLaminin Alpha-2–Congenital Muscular Dystrophy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesModalis Therapeutics Corp
China Registration ClassN/A

Develop Information

Active CompaniesModalis Therapeutics Corp
Inactive CompaniesN/A
Active IndicationsLaminin Alpha-2–Congenital Muscular Dystrophy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A